FOLFIRINOX

PRODIGE 4/ACCORD 11

ESMO
GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE

FOLFIRINOX PRODIGE 4/ACCORD 11

PRELIMINARY SCORE

CURATIVE

NON-CURATIVE

OS

ADJUSTMENTS

Quality of life

Delayed deterioration in global QoL

**Serious and disabling adverse effects**

Other adjustments

## FOLFIRINOX PRODIGE 4/ACCORD 11

SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

5

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers
Therapeutic Indication: First-line metastatic pancreatic cancer in patients with good performance status
Experimental Arm: FOLFIRINOX
Control Arm: Gemcitabine